GSK Terminates MIV-210 Partnership -- Medivir to Initiate Phase II Trial
HUDDINGE, Sweden, Dec. 27, 2004 (PRIMEZONE) -- Medivir AB (Stockholm: MVIRb.ST - news) announced today that GlaxoSmithKline (GSK) has terminated the research agreement for the developmental HIV compound MIV-210, as the compound doesn't satisfy GSK's desired profile. Based on preclinical data, provided by Medivir and GSK, including the resistance profiling of MIV-210, Medivir has decided to focus the further development of MIV-210 into drug experienced patients.
Medivir will initiate a phase IIa study in HIV drug experienced patients. It is expected that the trial will commence during 2005, at an estimated cost of less than 1 MUSD. The results from this trial should determine the effectiveness of MIV-210 in the treatment of drug experienced HIV patients, which represent a rapidly growing and disadvantaged segment of the HIV market.
"We have been very pleased with GSK as a partner for MIV-210. GSK's committed work has added key information and value to the project. Based on the currently available compound- and market data, Medivir has decided to continue the clinical development of MIV-210 at full speed, towards new commercial possibilities," says Medivir's CEO Lars Adlersson.
For further information please contact: Rein Piir CFO / IR Office: +46 8 546 831 23 or Mobile: +46 708 53 72 92
For additional information, please see Medivir's website www.medivir.com |
